topoisomerase


Also found in: Dictionary, Encyclopedia, Wikipedia.
Related to topoisomerase: DNA gyrase

topoisomerase

 [to″po-i´so-mer-ās]
an enzyme involved in mobilization and replication of DNA during cell division.

to·po·i·so·mer·ase

(tō'pō-i-som'ĕr-ās),
A type of enzyme converting (isomerizing) one topologic version of DNA into another; acts by catalyzing the breakage and reformation of DNA phosphodiester linkages.
[topo- + isomerase]

topoisomerase

(tō′pō-ī-sŏm′ə-rās′, -rāz′)
n.
Either of two isomerase enzymes that alter the topology of DNA molecules by breaking and reconnecting coiled strands.

topoisomerase

[to′po-i′so-mer-ās]
an enzyme involved in mobilization and replication of DNA during cell division.

topoisomerase

an enzyme involved in DNA replication that introduces a single-strand nick in the DNA enabling it to swivel and thereby relieve the accumulated winding strain generated during unwinding of the double helix.
References in periodicals archive ?
Evidence also suggests that the generation of ROS and the induction of topoisomerase Il-DNA complexes may play a role in curcumin-induced cancer cell death (Kuo et al.
Washington, August 29 ( ANI ): Researchers have claimed that problems with a key group of enzymes called topoisomerases could have profound effects on the genetic machinery behind development of brain and potentially lead to autism spectrum disorder (ASD).
Camptothecins with their docking score of their antineoplatic, topoisomerase I inhibitory, DNA intercatalor activity are shown in Tables 1,2 and 3.
In cancer, cells rapidly divide in an uncontrolled manner and topoisomerase inhibitors can block this uncontrolled cell division.
The finding that PARP inhibitors improve the anti-cancer activity of Topoisomerase 1 poisons indicates they may be useful in the treatment of bowel cancer.
The finding that they improve the anti-cancer activity of topoisomerase 1 poisons indicates they may be useful in treatment of bowel cancer.
The case of topoisomerase inhibitors is unusual in that these drugs have gone through the entire approval process for cancer.
Experiments have centred on a protein called topoisomerase II, which is attacked by the anti-cancer drug etoposide, regularly used to treat leukaemia.
X-ray crystallography has now revealed the atomic structure of a critical part of one of the relaxing callers, topoisomerase I, from the bacterium Escherichia coli.
This newly opened, randomized trial is designed to compare the efficacy of CRLX101, a nanopharmaceutical that inhibits both topoisomerase 1 and hypoxia-inducible factor-1 alpha (HIF-1), to topotecan as second-line therapy for relapsed SCLC.
According to the investigators, as many as one-third of patients with GIST may benefit from anthracyclines and topoisomerase inhibitors, based on the expression patterns of topoisomerases 1 (TOPO1, 34%) and 2A (TOPO2A, 32%).